State-of-the-art 3D Mammography Unit Arrives at Oswego Health’s Fulton Medical Center

Posted on July 12, 2021

MEDIA ADVISORY

Contact: Jamie Leszczynski, Sr. Director of Communications
(315) 523-1154
jleszczynski@oswegohealth.org

State-of-the-art 3D Mammography Unit Arrives at Oswego Health’s Fulton Medical Center
Genius™ 3D Mammography™ exams are clinically proven to increase invasive cancer detection and reduce recall rates1-7


(Fulton, NY - July 13, 2021)
Oswego Health is excited to offerGenius™3DMammography™ exams, developed by Hologic, Inc., a worldwide leader in Women’s Health. [i] Utilizing advanced breasttomosynthesis technology, Genius exams are clinically provento significantlyincreasethedetectionofbreastcancers anddecreasingthenumberofwomenaskedtoreturnforadditionaltesting.1-7

In conventional 2D Mammography, overlapping tissue is a leading reason why small breast cancers may be missed, and normal tissue may appear abnormal, leading to unnecessary callbacks. A Genius exam includes a three-dimensional method of imaging that can greatly reduce the tissue overlap effect.

A Genius exam includes both 2D images and tomosynthesis scans. Duringthetomosynthesis-DIMENSIONAL portionof theexam,anX-rayarm sweepsinaslightarcoverthebreast,takingmultiple images. A computer then converts the images into a stack of thin layers, allowing the radiologist to review the breast tissue one layer at a time. A Genius exam requires no additional compression and takes just a few seconds longer than a conventional 2D breast cancer screening exam.

Our Genius™ 3D Mammography™ exam, available on the 3Dimensions™ and Selenia® Dimensions® systems from Hologic, is revolutionizing how breast cancer is detected by providing a better option for women of all breast densities compared to 2D alone.1-2  Researchers have found that:

 

•        The Genius™ 3D Mammography™ exam finds 20-65% more invasive breast cancers compared to 2D alone, an average increase of 41%.3

•        Only the Genius™ 3D Mammography™ exam is FDA approved as superior for women with dense breasts compared to 2D alone.1-2

•        The Genius™ 3D Mammography™ exam reduces callbacks by up to 40% compared to 2D alone.2,4

 

Oswego Health is committed to the fight against breast cancer. In offering the Genius exam, Oswego Health provides a more accurate tool for breast cancer screening.1-7

If you would like to schedule a Genius 3D Mammography™ exam or have questions about this important breast health procedure, please contact Fulton Medical Imaging at 315-349-5540.

 

You are invited to join us on Wednesday, July 14th as Oswego Health will have leading medical experts explain the importance of being screened and you can see the technology first-hand. As a prominent female leader in the community, Mayor Deana Michaels will also personally have her screening done before the event and will share her personal experience with the exam with a message to the community.

When: July 14, 2021, at 12:00 pm

Where: Fulton Medical Center; 510 S. 4th St., Fulton

Remarks to be presented by – Mayor Michaels, Dr. Lisa Lai, Dr. David Wang, and Carolyn Handville

 

For more information about Oswego Health, please visit  www.oswegohealth.org.

 

AboutGenius™3DMammography™ Exams

The breast is a three-dimensional object composed of different structures located at different heights within the breast. These structures can overlap and cause confusion when viewed as a flat two-dimensional image. This confusion of overlapping of tissue is a leading reason why small breast cancers may be missed, and normal tissue may appear abnormal, leading to unnecessary callbacks. Using breast tomosynthesis technology, the Hologic system creates a 3-dimensional image of the breast structure, which enables radiologists to more clearly see through overlapping tissue to detect cancers, often at an earlier stage.

The Hologic system is the first FDA-approved breast tomosynthesis system in the U.S. Hologic Genius 3D Mammography™ exams are now available in all 50 states and over 50 countries. To date, more than 8 million women have been screened with this advanced screening system.

 

 

###



The Genius™ 3D Mammography™ (a.k.a. Genius™ exam) is acquired on the Hologic® 3D Mammography™ system and consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set. The Genius™ exam is only available on the Hologic 3D Mammography™ system.

References:

1) FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005

2) Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.

3) Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499 2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.

4) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.

5) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis(3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.

6) McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737-43.

7) Rafferty EA, Durand MA, Conant EF, et al Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts. JAMA. 2016 Apr 26;315(16):1784-6.

 

Other Member News

CNY Biotech Accelerator - 2026 Events / Pitch Opportunity
January 14, 2026

CNY Biotech Accelerator - 2026 Events / Pitch Opportunity

The Central New York Biotech Accelerator is hosting or partnering on exciting events and has a full complement of virtual sessions schedu

January 14, 2026

Oswego Health Offers After-Hours Urology Clinic to Better Serve Busy Patients

This new clinic offers convenient evening appointments for patients experiencing ongoing or complex urologic conditions.

Oswego Health
January 14, 2026

Oswego Health Employees Raise More Than $78,000 to Support Patient Comfort and Care

A total of 492 employees participated, exceeding the participation goal of 375 employees and surpassing last year’s fundraising total.

Excellus BCBS
January 14, 2026

2026 Health Equity Innovation Awards

At Excellus BlueCross BlueShield the health of our communities is at the center of everything we do.

United Way of Central New York Appoints Carrie Large as new President and CEO
January 14, 2026

United Way of Central New York Appoints Carrie Large as new President and CEO

Large will join the United Way of Central New York after most recently serving as the executive director of the Friends of the Rosamond Gifford Zoo.

January 13, 2026

Autism Acceptance Walk

This event is packed with fun, games, prizes, a photo booth and more.

J Rossi pic
January 13, 2026

Modern Advocacy Named to City & State's 2026 Who’s Who in Political Consulting

City & State’s Who’s Who in Political Consulting & Communications puts a spotlight on the PR and political comms pros who are on the front lines of the biggest campaigns in New York and beyond.

MHEDA MVP Award
January 13, 2026

Thompson & Johnson Earns MHEDA MVP Award for 10th Consecutive Year

The MVP Award is one of the most coveted honors in the material handling industry.

Barton & Loguidice Founders from 1961 (Left to Right) Frank Loguidice, James Clyde, Ken Brown, Edwin Barton
January 12, 2026

Barton & Loguidice Celebrates 65 Years of Service, Growth and Innovation

The firm is commemorating more than six decades of service to clients and communities across the region.